| Product Code: ETC8565449 | Publication Date: Sep 2024 | Updated Date: Apr 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, New Zealand continued to see steady growth in neuroprotective agents imports, with key suppliers including Australia, Metropolitan France, Spain, Ireland, and Germany. The market remained competitive, as indicated by the low Herfindahl-Hirschman Index (HHI) concentration. Despite a slight decline in growth rate from 2023 to 2024, the compound annual growth rate (CAGR) for the period of 2020-2024 stood at a healthy 3.11%. This data suggests a stable demand for neuroprotective agents in New Zealand, with a diverse range of sources supplying the market.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 New Zealand Neuroprotective Agents Market Overview |
3.1 New Zealand Country Macro Economic Indicators |
3.2 New Zealand Neuroprotective Agents Market Revenues & Volume, 2022 & 2032F |
3.3 New Zealand Neuroprotective Agents Market - Industry Life Cycle |
3.4 New Zealand Neuroprotective Agents Market - Porter's Five Forces |
3.5 New Zealand Neuroprotective Agents Market Revenues & Volume Share, By Drug Class, 2022 & 2032F |
3.6 New Zealand Neuroprotective Agents Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.7 New Zealand Neuroprotective Agents Market Revenues & Volume Share, By Route of Administration, 2022 & 2032F |
3.8 New Zealand Neuroprotective Agents Market Revenues & Volume Share, By Distribution Cahnnel, 2022 & 2032F |
4 New Zealand Neuroprotective Agents Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurological disorders in New Zealand |
4.2.2 Growing awareness about the importance of neuroprotective agents in healthcare |
4.2.3 Technological advancements in the development of neuroprotective agents |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in New Zealand |
4.3.2 High costs associated with research and development of neuroprotective agents |
4.3.3 Limited reimbursement policies for neuroprotective treatments |
5 New Zealand Neuroprotective Agents Market Trends |
6 New Zealand Neuroprotective Agents Market, By Types |
6.1 New Zealand Neuroprotective Agents Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 New Zealand Neuroprotective Agents Market Revenues & Volume, By Drug Class, 2022 - 2032F |
6.1.3 New Zealand Neuroprotective Agents Market Revenues & Volume, By Anesthetics, 2022 - 2032F |
6.1.4 New Zealand Neuroprotective Agents Market Revenues & Volume, By Antagonists, 2022 - 2032F |
6.1.5 New Zealand Neuroprotective Agents Market Revenues & Volume, By Antidepressants, 2022 - 2032F |
6.1.6 New Zealand Neuroprotective Agents Market Revenues & Volume, By Cytokines, 2022 - 2032F |
6.1.7 New Zealand Neuroprotective Agents Market Revenues & Volume, By Others, 2022 - 2032F |
6.2 New Zealand Neuroprotective Agents Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 New Zealand Neuroprotective Agents Market Revenues & Volume, By Alzheimer's disease, 2022 - 2032F |
6.2.3 New Zealand Neuroprotective Agents Market Revenues & Volume, By Dementia, 2022 - 2032F |
6.2.4 New Zealand Neuroprotective Agents Market Revenues & Volume, By Epilepsy, 2022 - 2032F |
6.2.5 New Zealand Neuroprotective Agents Market Revenues & Volume, By Multiple sclerosis, 2022 - 2032F |
6.2.6 New Zealand Neuroprotective Agents Market Revenues & Volume, By Others, 2022 - 2032F |
6.3 New Zealand Neuroprotective Agents Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 New Zealand Neuroprotective Agents Market Revenues & Volume, By Oral, 2022 - 2032F |
6.3.3 New Zealand Neuroprotective Agents Market Revenues & Volume, By Topical, 2022 - 2032F |
6.3.4 New Zealand Neuroprotective Agents Market Revenues & Volume, By Epidural, 2022 - 2032F |
6.3.5 New Zealand Neuroprotective Agents Market Revenues & Volume, By Intravenous, 2022 - 2032F |
6.4 New Zealand Neuroprotective Agents Market, By Distribution Cahnnel |
6.4.1 Overview and Analysis |
6.4.2 New Zealand Neuroprotective Agents Market Revenues & Volume, By Hospital Pharmacies, 2022 - 2032F |
6.4.3 New Zealand Neuroprotective Agents Market Revenues & Volume, By Retail Pharmacies, 2022 - 2032F |
6.4.4 New Zealand Neuroprotective Agents Market Revenues & Volume, By Drug Stores, 2022 - 2032F |
6.4.5 New Zealand Neuroprotective Agents Market Revenues & Volume, By Online Pharmacies, 2022 - 2032F |
7 New Zealand Neuroprotective Agents Market Import-Export Trade Statistics |
7.1 New Zealand Neuroprotective Agents Market Export to Major Countries |
7.2 New Zealand Neuroprotective Agents Market Imports from Major Countries |
8 New Zealand Neuroprotective Agents Market Key Performance Indicators |
8.1 Number of clinical trials conducted for neuroprotective agents in New Zealand |
8.2 Adoption rate of neuroprotective agents among healthcare providers |
8.3 Percentage of patients with neurological disorders receiving neuroprotective treatments |
9 New Zealand Neuroprotective Agents Market - Opportunity Assessment |
9.1 New Zealand Neuroprotective Agents Market Opportunity Assessment, By Drug Class, 2022 & 2032F |
9.2 New Zealand Neuroprotective Agents Market Opportunity Assessment, By Application, 2022 & 2032F |
9.3 New Zealand Neuroprotective Agents Market Opportunity Assessment, By Route of Administration, 2022 & 2032F |
9.4 New Zealand Neuroprotective Agents Market Opportunity Assessment, By Distribution Cahnnel, 2022 & 2032F |
10 New Zealand Neuroprotective Agents Market - Competitive Landscape |
10.1 New Zealand Neuroprotective Agents Market Revenue Share, By Companies, 2025 |
10.2 New Zealand Neuroprotective Agents Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here